Home Stock

Stock Research: Kiniksa Pharmaceuticals

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Kiniksa Pharmaceuticals

NSQ:KNSA GB00BRXB0C07
n/a
  • Value
    4
  • Growth
    100
  • Safety
    Safety
    n/a
  • Combined
    n/a
  • Sentiment
    80
  • 360° View
    360° View
    n/a
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

more

ANALYSIS: We are missing some facts for this section. For this reason, we refrain from providing a description our analysis.

more
Strongest Rank Dividend Yield
Weakest Rank Growth
Country United Kingdom
Industry Biotechnology
Size Medium
Website kiniksa.com
Index
NASDAQ
Kiniksa Pharmaceuticals stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 n/a n/a n/a
Growth
100 n/a n/a n/a
Safety
Safety
n/a n/a n/a n/a
Sentiment
80 n/a n/a n/a
360° View
360° View
n/a n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
71 n/a n/a n/a
Opinions Change
91 n/a n/a n/a
Pro Holdings
n/a n/a n/a n/a
Market Pulse
16 n/a n/a n/a
Sentiment
80 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
4 n/a n/a n/a
Growth
100 n/a n/a n/a
Safety Safety
n/a n/a n/a n/a
Combined
n/a n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
23 n/a n/a n/a
Price vs. Earnings (P/E)
8 n/a n/a n/a
Price vs. Book (P/B)
25 n/a n/a n/a
Dividend Yield
1 n/a n/a n/a
Value
4 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
84 n/a n/a n/a
Profit Growth
78 n/a n/a n/a
Capital Growth
65 n/a n/a n/a
Stock Returns
95 n/a n/a n/a
Growth
100 n/a n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
95 n/a n/a n/a
Refinancing
34 n/a n/a n/a
Liquidity
n/a n/a n/a n/a
Safety Safety
n/a n/a n/a n/a

Similar Stocks

Discover high‑ranked alternatives to Kiniksa Pharmaceuticals and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Metlen Energy & Metals

LSE:MTLN
Country: United Kingdom
Industry: Industrial Conglomerates
Size: Large
Full Stock Analysis

ZIGUP

LSE:ZIG
Country: United Kingdom
Industry: Specialized Consumer Services
Size: Medium
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

n/a

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews